Literature DB >> 11597812

Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas.

B J Fisher1, C C Leighton, O Vujovic, D R Macdonald, L Stitt.   

Abstract

PURPOSE: To document the incidence of tumor progression in pediatric patients with low-grade gliomas (LGGs), with particular emphasis on those patients who did not receive postoperative chemotherapy or radiotherapy (RT). METHODS AND MATERIALS: A database of 128 patients with histologically confirmed LGGs (World Health Organization Grade I-II), age <or=18 years, who had been referred to the London Regional Cancer Center and Dalhousie University between 1979 and 1995, was compiled.
RESULTS: The median follow-up for the 128 patients was 7.3 years. Of the 128 patients, 63 were male and 65 female. The median age was 7.0 years (range 0-18). Twenty-five patients underwent gross complete resection, 63 subtotal resection, and 40 patients biopsy. Ninety-one percent (n = 117) of the tumors were astrocytomas, of which 22 were pilocytic, 3 were oligodendrogliomas, 7 were mixed gliomas, and 1 was a ganglioglioma. Of the 103 subtotally resected patients, 48 received postoperative RT (median dose 59 Gy in 25 fractions) and 10 patients were irradiated at the time of tumor progression. The 5-year overall survival was 86%, cause-specific survival 88%, and 5-year progression-free survival 79%. The results of the univariate analysis of the overall survival by the Wilcoxon model were statistically significant for Karnofsky performance status (p = 0.03), RT timing (i.e., postoperative vs. deferred; p = 0.05), and tumor location (p = 0.02). The analysis of progression-free survival confirmed the statistical significance of the extent of surgical resection (i.e., complete vs. subtotal resection; p = 0.02). None of the patients who underwent gross complete resections received postoperative RT and none developed tumor recurrence. Of the 103 patients who had subtotal resections, 33 had progression, with a median postprogression survival of 39 months. The rate of tumor progression among the subtotally resected LGG patients who did not receive immediate postoperative RT was 42%. The timing of RT and tumor location lost statistical significance for overall survival when the completely resected patients were excluded from the analysis.
CONCLUSIONS: The extent of surgical resection was prognostically significant for progression-free survival but lost significance as a prognostic factor once the complete resection patients were excluded from the analysis. At a median survival of 7.3 years, 42% of the subtotally resected LGG patients who did not receive immediate postoperative RT had tumor progression. No statistically significant difference in survival was seen between the postoperative and deferred RT groups, even though the postoperative RT group was a group with poorer prognostic features (bulky residual tumor postoperatively, Karnofsky performance status <70, and nonhemispheric, noncerebellar tumors), indicating that RT may be beneficial for this particular subset of patients.

Entities:  

Mesh:

Year:  2001        PMID: 11597812     DOI: 10.1016/s0360-3016(01)01705-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  26 in total

1.  Neurofibromatosis 1-associated optic pathway gliomas.

Authors:  Ben Shofty; Liat Ben Sira; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-11       Impact factor: 1.475

2.  Interstitial iodine-125 radiosurgery alone or in combination with microsurgery for pediatric patients with eloquently located low-grade glioma: a pilot study.

Authors:  A Peraud; C Goetz; A Siefert; J C Tonn; F W Kreth
Journal:  Childs Nerv Syst       Date:  2006-09-14       Impact factor: 1.475

Review 3.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

4.  Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging.

Authors:  Albert H Kim; Elizabeth A Thompson; Lance S Governale; Catalina Santa; Kevin Cahll; Mark W Kieran; Susan N Chi; Nicole J Ullrich; R Michael Scott; Liliana C Goumnerova
Journal:  J Neurosurg Pediatr       Date:  2014-07-25       Impact factor: 2.375

5.  Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children.

Authors:  Mee Jeong Lee; Young Shin Ra; Jun Bum Park; Hyun Woo Goo; Seung Do Ahn; Shin Kwang Khang; Joon Sup Song; Yoon Jung Kim; Thad T Ghim
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

Review 6.  Treatments for astrocytic tumors in children: current and emerging strategies.

Authors:  Stanislaw R Burzynski
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 7.  Radiotherapy for pediatric central nervous system tumors: a regional cancer centre experience.

Authors:  Glenn Bauman; Barbara Fisher; Elizabeth Cairney; Adriana Ranger; A Rashid Dar; Jill Ross; Larry Stitt; David MacDonald
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

8.  Cytogenetic analysis of paediatric astrocytoma using comparative genomic hybridisation and fluorescence in-situ hybridisation.

Authors:  Samantha J Ward; Katherine Karakoula; Kim P Phipps; William Harkness; Richard Hayward; Dominic Thompson; Thomas S Jacques; Brian Harding; John L Darling; David G T Thomas; Tracy J Warr
Journal:  J Neurooncol       Date:  2010-01-06       Impact factor: 4.130

9.  Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children.

Authors:  Ting-Rong Hsu; Tai-Tong Wong; Feng-Chi Chang; Donald M Ho; Ren-Bin Tang; Peck-Foong Thien; Kai-Ping Chang
Journal:  Childs Nerv Syst       Date:  2008-09-04       Impact factor: 1.475

10.  Management of low-grade gliomas in childhood.

Authors:  Ian F Pollack
Journal:  World Neurosurg       Date:  2013-02-01       Impact factor: 2.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.